

Special Issue

Brain Metastases in Breast Cancer

Message from the Guest Editors

Breast cancer is the second most frequent cause of brain metastases after lung cancer, with an estimated occurrence of 10–30%. Paradoxically, increased efficacy of breast cancer treatment allows more time for the development of brain metastases. In consequence, this problem is becoming increasingly important and remains an unmet need. The prognosis of breast cancer patients with brain metastases is generally poor. Their management includes neurosurgery, radiotherapy, and systemic therapies. Most anticancer agents show limited penetrance through the blood-brain barrier, making the brain a “sanctuary site.” Recently, there has been a shift from combating established brain metastases to preventive strategies. The knowledge on the mechanisms of brain-specific metastatic process and on the role of the unique brain microenvironment is still limited. Currently available molecular techniques allow analysis of thousands of genes, and researchers have hopes they can pave the way to new preventive and therapeutic strategies.

Guest Editors

Prof. Dr. Renata Duchnowska

Department of Oncology, Military Institute of Medicine, Szaserów 128 St., 04–141 Warsaw, Poland

Prof. Dr. Philippe Métellus

Department of Neurosurgery Clairval Hospital Center, Generale de Santé, 317 Boulevard du Redon 1009, 13009 Marseille, France

Deadline for manuscript submissions

closed (15 May 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/59786

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)